跳至主要内容
临床试验/NCT07737158
NCT07737158尚未招募不适用

Efficacy and Safety of Venlafaxine in the Treatment of Non-specific Low Back Pain

Beijing Tiantan Hospital1 个研究点 分布在 1 个国家目标入组 228 人开始时间: 2026年9月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
228
试验地点
1
主要终点
Change From Baseline in Average Low Back Pain Intensity at Month 3

研究概览

简要总结

Chronic non-specific low back pain is the leading cause of productivity loss and disability worldwide, constituting a major public health challenge. This study aims to systematically evaluate and compare the role of the antidepressant drug Venlafaxine in chronic non-specific low back pain, which is of critical importance for optimising clinical practice and developing precise, individualised treatment regimens.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults aged 18 to 75 years.
  • Diagnosis of chronic nonspecific low back pain, defined as pain located below the costal margin and above the inferior gluteal folds, lasting for more than 3 months, without a specific pathological cause.
  • Moderate to severe pain, defined as a Numerical Rating Scale score of 3 or higher.
  • Able to understand the study procedures and sign written informed consent.

排除标准

  • Low back pain caused by a known specific pathological condition, including but not limited to fracture, malignancy, infection, inflammatory disease, or other identifiable structural or systemic causes.
  • Major comorbidities that may interfere with study outcomes or represent contraindications to the study medication.
  • Current or previous diagnosis of depression, regardless of whether treatment was received.
  • Current or previous use of antidepressant medication.
  • Current use of opioid analgesics.
  • Pregnancy, breastfeeding, or planned pregnancy during the study period.
  • Known allergy, hypersensitivity, or contraindication to toludesvenlafaxine.
  • History of psychosis or other major psychiatric disorders.
  • Any condition that, in the investigator's judgment, makes the participant unsuitable for the study.

结局指标

主要结局

Change From Baseline in Average Low Back Pain Intensity at Month 3

时间窗: 3 months after randomization

Average low back pain intensity during the previous week will be assessed using an 11-point Numerical Rating Scale, ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain.

次要结局

  • Incidence of Adverse Events(From randomization to 6 months after randomization)
  • Change From Baseline in Average Low Back Pain Intensity(Baseline, 1 month, and 6 months after randomization)
  • Change From Baseline in Functional Disability Assessed by the Roland-Morris Disability Questionnaire(Baseline, 1 month, 3 months, and 6 months after randomization)
  • Global Perceived Recovery(1 month, 3 months, and 6 months after randomization)
  • Change From Baseline in Health-related Quality of Life Assessed by EQ-5D-5L(Baseline, 1 month, 3 months, and 6 months after randomization)
  • Change From Baseline in Sleep Quality Assessed by the Insomnia Severity Index(Baseline, 1 month, 3 months, and 6 months after randomization)
  • Change From Baseline in Back Pain Beliefs Assessed by the Back Beliefs Questionnaire(Baseline, 1 month, 3 months, and 6 months after randomization)
  • Change From Baseline in Neuropathic Pain Features Assessed by the painDETECT Questionnaire(Baseline, 1 month, 3 months, and 6 months after randomization)
  • Use of Nonsteroidal Anti-inflammatory Drugs(Baseline, 1 month, 3 months, and 6 months after randomization)

研究者

发起方
Beijing Tiantan Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Fang Luo

Director of Department of Pain Management

Beijing Tiantan Hospital

研究点 (1)

Loading locations...

相似试验